Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
ECDD Technical summary
In the "spinal dog" 5-methoxy-3,4-methylenedioxyamphetamine (MMDA) has a pharmacological profile that resembles that of both LSD and amphetamine, but it also has other properties not exhibited by either drug. There are no data available on its toxicology, pharmacokinetics, dependence potential, nature and magnitude of associated public health or social problems, or epidemiology of its use and abuse. The substance is under national control in five countries. It has no known therapeutic use and ‘no information is available concerning its production. There are some reports from the USA of minor incidences of illicit trafficking in this substance. On the basis of the data outlined above, it was the consensus of the Expert .Committee that 5-methoxy-3,4-methylenedioxyamphetamine met the criteria of article 2, paragraph 4, for control under the Convention on Psychotropic Substances. Since it has no known therapeutic use, the Expert Committee recommended that it be placed in Schedule I of the Convention.
In the "spinal dog" 5-methoxy-3,4-methylenedioxyamphetamine (MMDA) has a pharmacological profile that resembles that of both LSD and amphetamine, but it also has other properties not exhibited by either drug. There are no data available on its toxicology, pharmacokinetics, dependence potential, nature and magnitude of associated public health or social problems, or epidemiology of its use and abuse. The substance is under national control in five countries. It has no known therapeutic use and ‘no information is available concerning its production. There are some reports from the USA of minor incidences of illicit trafficking in this substance. On the basis of the data outlined above, it was the consensus of the Expert .Committee that 5-methoxy-3,4-methylenedioxyamphetamine met the criteria of article 2, paragraph 4, for control under the Convention on Psychotropic Substances. Since it has no known therapeutic use, the Expert Committee recommended that it be placed in Schedule I of the Convention.
ECDD Recommendation
Inclusion in Schedule I of the 1971 Convention on Psychotropic Substances
Link to full TRS
who_trs_729.pdf1.29 MB